Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 910 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: morphine Clear all
Completed Phase 4 Interventional Results available

Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome

NCT02851303
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
0 Hours to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

NCT04448561
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8082, morphine, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 19, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Temozolomide, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
View directory record Official record
Conditions
Acute Pain
Interventions
Oxymorphone immediate release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

NCT01055704
View directory record Official record
Conditions
Gastric Motility Disorder
Interventions
Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 19, 2026, 6:21 AM EDT
Recruiting Phase 3 Interventional

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585
View directory record Official record
Conditions
Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions
Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Intravenous Hydromorphone to Usual Care

NCT01429298
View directory record Official record
Conditions
Pain
Interventions
Hydromorphone, Usual care
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 4 Interventional

Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

NCT02391844
View directory record Official record
Conditions
Disorder of Knee
Interventions
Oxycodone
Drug
Lead sponsor
International Clinical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

NCT00699010
View directory record Official record
Conditions
Opioid Abuse
Interventions
Acurox 5/30mg taken first, Oxycodone 5mg taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 19, 2026, 6:21 AM EDT
Not yet recruiting Not applicable Interventional

Readiness Outcomes Affecting Return to Sport 3.0

NCT07476430
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Mental Skills Training (MST)
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction

NCT03893175
View directory record Official record
Conditions
Impacted Third Molar Tooth, Pain, Acute
Interventions
Ibuprofen, Acetaminophen, Placebo, Oxycodone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 19, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00277836
View directory record Official record
Conditions
Neoplasms
Interventions
MST-997
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2006 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Management of Postoperative Pain After Total Knee Replacement.

NCT01163214
View directory record Official record
Conditions
Postoperative Pain, Knee Replacement Arthroplasty
Interventions
Nerve Block, Periarticular Injection
Drug
Lead sponsor
Mark J. Spangehl, M.D.
Other
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 19, 2026, 6:21 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Opioid Use After Laparoscopic Salpingectomy

NCT06434233
View directory record Official record
Conditions
Opioid Use, Post-operative Pain, Sterility, Female
Interventions
Acetaminophen, Ibuprofen, Oxycodone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 6:21 AM EDT
Recruiting No phase listed Observational

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

NCT07278375
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Not listed
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
0 Minutes and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transversus Abdominis Plane Block

NCT06274307
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Transversus abdominis plane block
Procedure
Lead sponsor
Justin Hruska
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 19, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Postoperative Pain Control & Relief in Neonates

NCT03677830
View directory record Official record
Conditions
Pain, Postoperative, Premature Infant, Opioid Use
Interventions
Acetaminophen, Saline
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 1 Month
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 19, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

NCT01609062
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 19, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

NCT03996694
View directory record Official record
Conditions
Respiratory Depression
Interventions
Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 19, 2026, 6:21 AM EDT